Bayer’s Finerenone hits target in Phase III FIDELIO-DKD renal outcomes study Reuters Jul 11, 2020 The company claims that finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor antagonist to…
Bayer’s digital health solutions provide women with accessible advice on endometriosis and… EH News Bureau Jan 31, 2020 Bayer’s Bare Your Pain application and Ask Tanu chatbot aim to empower women by addressing misinformation on endometriosis and…
